(ARTO trial-NCT03449719): Role of local treatment after progression in patients with castrate-resistant prostate cancer undergoing first-line abiraterone treatment.

被引：0
|
作者：
Francolini, Giulio
Di Cataldo, Vanessa
Detti, Beatrice
Garlatti, Pietro
Caini, Saverio
Bruni, Alessio
Ingrosso, Gianluca
D'Angelillo, Rolando Maria
Alitto, Anna Rita
Augugliaro, Matteo
Triggiani, Luca
Parisi, Silvana
Facchini, Gaetano
Banini, Marco
Simontacchi, Gabriele
Desideri, Isacco
Meattini, Icro
Valicenti, Richard K.
Livi, Lorenzo
机构：
[1] Univ Florence, Radiat Oncol Unit, Azienda Osped Univ Careggi, Florence, Italy
[2] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy
[3] Inst Canc Res Prevent & Clin Network, Canc Risk Factors & Life Style Epidemiol Unit, Florence, Italy
[4] Univ Hosp Modena, Dept Oncol & Hematol, Radiotherapy Unit, Modena, Italy
[5] Univ Perugia, Radiat Oncol Sect, Dept Med & Surg, Perugia, Italy
[6] Univ Roma Tor Vergata, Radiat Oncol, Dept Biomed & Prevent, Rome, Italy
[7] Fdn Policlin Univ A Gemelli IRCCS, UOC Radioterapia Oncol, Dipartimento Diagnost Immagini Radioterapia Oncol, Rome, Italy
[8] Azienda USL IRCCS Reggio Emilia, Unit Radiotherapy, Reggio Emilia, Italy
[9] Univ Brescia, Dept Radiat Oncol, Brescia, Italy
[10] Univ Messina, Radiat Oncol Unit, Dept Biomed Dent Sci & Morphol & Funct Images, Messina, Italy
[11] SM Grazie Hosp, Med Oncol Unit, Naples, Italy
[12] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-137-3222-3876-5567; 130-540-543-12277-2683; 261-265; 261-566-11347; 3282-270-434-2806; 283-2494-5577-2829; 7; 5; 3; 2; 162; 175; 3617; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：130 / 130
页数：1
相关论文
共 50 条
  • [21] Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer
    de Liano, A. G.
    Reig, O.
    Mellado, B.
    Martin, C.
    Rull, E. U.
    Maroto, J. P.
    BRITISH JOURNAL OF CANCER, 2014, 110 (09) : 2201 - 2208
  • [22] CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel
    Wissing, Michel D.
    Coenen, Jules L. L. M.
    van den Berg, Pieter
    Westgeest, Hans M.
    van den Eertwegh, Alfons J. M.
    van Oort, Inge M.
    Bos, Monique M.
    Bergman, Andre M.
    Hamberg, Paul
    ten Tije, Albert J.
    Los, Maartje
    Lolkema, Martijn P. J. K.
    de Wit, Ronald
    Gelderblom, Hans
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (06) : E760 - E772
  • [23] ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis.
    Francolini, Giulio
    Garlatti, Pietro
    Loi, Mauro
    Detti, Beatrice
    Aquilano, Michele
    Allegra, Andrea
    Guerrieri, Barbara
    Salvestrini, Viola
    Pinzani, Pamela
    Bellini, Chiara
    Salvianti, Francesca
    Stocchi, Giulia
    Ciccone, Lucia Pia
    Salvatore, Giulia
    Sottili, Mariangela
    Di Cataldo, Vanessa
    Desideri, Isacco
    Mangoni, Monica
    Meattini, Icro
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [24] ARTO trial: Overall survival analysis from a randomized phase II trial testing the benefit of adding stereotactic body radiotherapy to abiraterone acetate in patients with oligometastatic castrate-resistant prostate cancer.
    Francolini, Giulio
    Di Cataldo, Vanessa
    Garlatti, Pietro
    Detti, Beatrice
    Caini, Saverio
    Bruni, Alessio
    Ingrosso, Gianluca
    D'Angelillo, Rolando Maria
    Alitto, Anna Rita
    Augugliaro, Matteo
    Triggiani, Luca
    Parisi, Silvana
    Facchini, Gaetano
    Banini, Marco
    Simontacchi, Gabriele
    Desideri, Isacco
    Meattini, Icro
    Valicenti, Richard K.
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 132 - 132
  • [25] R75251 IN PROSTATE-CANCER PATIENTS IN PROGRESSION AFTER FIRST-LINE HORMONAL TREATMENT
    BOCCARDO, F
    CANNATA, D
    GUARNERI, D
    ONETO, F
    CORTESI, E
    BONO, A
    TUMORI, 1994, 80 (04) : 276 - 279
  • [26] REDUCED DOSE ABIRATERONE ACETATE WITH CONCOMITANT LOW DOSE PREDNISONE IN THE TREATMENT OF ≥85 YEARS AGED PATIENTS WITH ADVANCED CASTRATE-RESISTANT PROSTATE CANCER
    Roviello, Giandomenico
    Francini, Edoardo
    Fiaschi, Anna Ida
    Laera, Letizia
    Miano, Salvatora Tindara
    Petrioli, Roberto
    ANTICANCER RESEARCH, 2015, 35 (06) : 3633 - 3633
  • [27] TREATMENT EFFECT AND COSTS OF THE COMPLETE THERAPEUTIC PATHWAY IN PATIENTS WITH FIRST-LINE CASTRATION-RESISTANT PROSTATE CANCER WITH EITHER FIRST-LINE DOCETAXEL OR ABIRATERONE ACETATE PLUS PREDNISONE
    Holleman, M. S.
    Santi, I
    Huygens, S.
    Aben, K. K. H.
    Van den Bergh, A. C. M.
    Bergman, A. M.
    van den Eertwegh, A. J. M.
    Kuppen, M. C. P.
    Lavalaye, J.
    Mehra, N. M.
    van Moorselaar, R. J. A.
    Van Oort, I. M.
    Somford, D. M.
    Westgeest, H. M.
    Gerritsen, W. R.
    Uyl-De Groot, C. A.
    VALUE IN HEALTH, 2022, 25 (01) : S266 - S267
  • [28] Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone
    Nieblas-Toscano, D.
    Arenas-Bonilla, A. J.
    Flores-Martin, J. F.
    Gutierrez-Tejero, F.
    Velarde-Munoz, C.
    Ramos-Alaminos, C., I
    Salas-Moreno, M. C.
    Galisteo-Moya, R.
    Moreno-Jimenez, J.
    ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (03): : 164 - 171
  • [29] Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial
    Fizazi, K.
    Delva, R.
    Gravis, G.
    Baciarello, G.
    Theodore, C.
    Gross-Goupil, M.
    Bompas, E.
    Lobbedez, F. Joly
    Tazi, Y.
    L'Haridon, T.
    Hon, T. Nguyen Tan
    Barthelemy, P.
    Culine, S.
    Berdah, J-F.
    Deblock, M.
    Beuzeboc, P.
    Flechon, A.
    Cheneau, C.
    Martineau, G.
    Borget, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer
    McNamara, Megan Ann
    Oyekunle, Taofik
    Chin, Bennett B.
    Oldan, Jorge
    Anand, Aseem
    Ritz, Michala
    Shantzer, Lindsey
    Anand, Monika
    Armstrong, Andrew J.
    George, Daniel J.
    PROSTATE, 2019, 79 (10): : 1106 - 1116
12345